Publications by authors named "A F Hoo"
Article Synopsis
- VYC-25L is a hyaluronic acid filler approved in 2019 for facial volumizing, lifting, and contouring, offering a long-lasting effect of at least 24 months.
- Experienced doctors highlight its unique properties, including high lift capacity, moldability, and tissue integration, which enhance its use in non-surgical facial aesthetics.
- Proper technique and cautious application are essential for maximizing patient benefits, including starting with the chin and jawline and following best practice principles to ensure safety and effectiveness.
Introduction: It remains unclear if prematurity itself can influence post delivery lung development and particularly, the bronchial size.
Aim: To assess lung function during the first two years of life in healthy preterm infants and compare the measurements to those obtained in healthy term infants during the same time period.
Methods: This observational longitudinal study assessed lung function in 74 preterm (30+0 to 35+6 weeks' gestational age) and 76 healthy term control infants who were recruited between 2011 and 2013.
Background: Comprehensive patient assessment and planning are central to esthetic treatment with injectables. MD ASA™ (Multi-Dimensional Aesthetic Scan Assessment) is a novel tool developed for this purpose.
Aims: To describe the MD ASA technique and present its preliminary application.
Background: With the widespread introduction of newborn screening for cystic fibrosis (CF), there has been considerable emphasis on the need to develop objective markers of lung health that can be used during infancy. We hypothesised that in a newborn screened (NBS) UK cohort, evidence of airway inflammation and infection at one year would be associated with adverse structural and functional outcomes at the same age.
Methods: Infants underwent lung function testing, chest CT scan and bronchoscopy with bronchoalveolar lavage (BAL) at 1 year of age when clinically well.
The aim of this study is to examine factors that can predict mortality in patients that have veno-arterial extracorporeal membrane oxygenation (VA-ECMO) instituted for cardiogenic shock. A single-center, retrospective study of 127 patients who underwent VA-ECMO for cardiogenic shock between January 2003 and December 2017 was conducted. Eighty-three (65%) patients survived to weaning or bridging therapy.
View Article and Find Full Text PDF